Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis

Documenti analoghi

• Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy
  di: Ece Gokyayla, et al.
  Pubblicazione: (2025)
• Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors
  di: Mariano Ara‐Martín, et al.
  Pubblicazione: (2025)
• Vaccination Strategies in Atopic Dermatitis Patients Treated With JAK Inhibitors
  di: Nóra Belső
  Pubblicazione: (2025)
• Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: In‐Depth Analysis of Efficacy and Safety in the Phase 3 POETYK PSO ‐4 Trial
  di: Yukari Okubo, et al.
  Pubblicazione: (2025)
• Efficacy of Tralokinumab in Atopic Dermatitis Patients With Prior Biologic and JAK Inhibitor Therapy
  di: Alexandra Nigro, et al.
  Pubblicazione: (2026)